H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

Big business has an inside track in the second Trump presidency, and people with a stake in those businesses have reason to ...

Corporate earnings are coming in strong. Investors are also seeing the Trump administration take a less aggressive approach ...

The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.

Stargate CEOs cite project’s promise of enabling cancer vaccines, though Musk joins critics in questioning partners’ ...

The signs of a potential bird flu transmission have provided some respite to these vaccine-focused stocks, especially to those who made COVID-19 vaccines. Vaccine makers, especially Moderna and ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in acute respiratory illness due to higher rates of seasonal influenza ...

David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...

During a fireside chat at the annual J.P. Morgan Healthcare Conference on January 13th, Mayo Clinic chief administrative ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for ...